|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0007226,
umls-concept:C0008976,
umls-concept:C0036043,
umls-concept:C0039286,
umls-concept:C0246421,
umls-concept:C0279025,
umls-concept:C0549177,
umls-concept:C0936012,
umls-concept:C1522673,
umls-concept:C1705413
|
|
pubmed:issue |
36
|
|
pubmed:dateCreated |
2007-12-19
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Previous analyses of adjuvant studies of aromatase inhibitors versus tamoxifen, including the Breast International Group (BIG) 1-98 study, have suggested a small numerical excess of cardiac adverse events (AEs) on aromatase inhibitors, a reduction in the incidence of hypercholesterolemia on tamoxifen, and significantly higher incidence of thromboembolic AEs on tamoxifen. The purpose of the present study is to provide detailed updated information on these AEs in BIG 1-98.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:Castiglione-GertschMonicaM,
pubmed-author:CoatesAlan SAS,
pubmed-author:ColleoniMarcoM,
pubmed-author:ForbesJohn FJF,
pubmed-author:GelberRichard DRD,
pubmed-author:GoldhirschAronA,
pubmed-author:KeshaviahAparnaA,
pubmed-author:MauriacLouisL,
pubmed-author:MouridsenHenningH,
pubmed-author:ParidaensRobertR,
pubmed-author:PriceKaren NKN,
pubmed-author:RabaglioManuelaM,
pubmed-author:SmithIanI,
pubmed-author:SunZhuoxinZ,
pubmed-author:ThürlimannBeatB
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5715-22
|
|
pubmed:meshHeading |
pubmed-meshheading:17998546-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17998546-Breast Neoplasms,
pubmed-meshheading:17998546-Cardiovascular Diseases,
pubmed-meshheading:17998546-Chemotherapy, Adjuvant,
pubmed-meshheading:17998546-Female,
pubmed-meshheading:17998546-Humans,
pubmed-meshheading:17998546-Middle Aged,
pubmed-meshheading:17998546-Nitriles,
pubmed-meshheading:17998546-Tamoxifen,
pubmed-meshheading:17998546-Triazoles
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
|
|
pubmed:affiliation |
Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark. henning.mouridsen@rh.hosp.dk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
